Randomized trial of cisplatin and carboplatin versus cisplatin, vinblastine and bleomycin in ovarian cancer

Gynecologic and Obstetric Investigation

Volumn 50, Issue 4, 2000, Pages 269-274

  Kikkawa, Fumitaka ^a,d   Matsuzawa, Katsuji ^b   Arii, Yoshitaro ^c   Kawai, Michiyasu ^c   Kobayashi, Iwao ^a   Nakashima, Nobuo ^a   Mizutani, Shigehiko ^a  

^a NAGOYA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b ANJO KOSEI HOSPITAL   (Japan)

^c NAGOYA UNIVERSITY   (Japan)

^d NONE   (Japan)

Author keywords

Carboplatin; Chemotherapy; Cisplatin; Ovarian cancer

Indexed keywords

BLEOMYCIN; CARBOPLATIN; CISPLATIN; VINBLASTINE;

ADULT; ADVANCED CANCER; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; OVARY CANCER; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; REGRESSION ANALYSIS; TREATMENT OUTCOME;

EID: 0033652975     PISSN: 03787346     EISSN: None     Source Type: Journal    
DOI: 10.1159/000010330     Document Type: Article

References (21)

1. A randomized trial of cyclophosphamide and doxorubicin with or without cisplatin in advanced ovarian carcinoma. A Gynecologic Oncology Group Study
2. Intraperitoneal chemotherapy versus no treatment in patients with ovarian carcinoma who are in complete clinical remission
3. Radical surgical procedure improves survival time in patients with recurrent ovarian cancer
4. Prognostic evaluation of lymphadenectomy for epithelial ovarian cancer
5. Prognostic factors in advanced epithelial ovarian cancer
6. Meta-analysis of cisplatin, doxorubicin, and cyclophosphamide versus cisplatin and cyclophosphamide chemotherapy of ovarian carcinoma
7. Combined carboplatin and cisplatin
8. High dose platinum consisting of combined carboplatin and cisplatin in previously untreated ovarian cancer patients with residual disease
9. Cisplatin combined with carboplatin: A new way of intensification of platinum dose in the treatment of advanced ovarian cancer
10. Clinical remission criteria for epithelial carcinoma of the ovary
11. A randomized trial of cisplatin, vinblastine, and bleomycin versus cyclophosphamide, aclacinomycin, and cisplatin in epithelial ovarian cancer
12. Combined cisplatin and carboplatin chemotherapy for treatment of advanced epithelial ovarian cancer
13. Randomized study of two doses of cisplatin and cyclophosphamide in epithelial ovarian cancer
14. Mature results of a randomised trial of two doses of cisplatin for the treatment of ovarian cancer
15. Assessment of dose-intensive therapy in suboptimally debulked ovarian cancer: A Gynaecological Oncology Group Study
16. Carboplatin, doxorubicin and cyclophosphamide versus cisplatin, doxorubicin and cyclophosphamide: A randomized trial in stage III-IV epithelial ovarian carcinoma
17. Improved therapeutic index of carboplatin plus cyclophosphamide versus cisplatin plus cyclophosphamide: Final report by the Southwest Oncology Group of a phase III randomized trial in stages III and IV ovarian cancer
18. Randomized study comparing carboplatin/cyclophosphamide and cisplatin/cyclophosphamide as first-line treatment in patients with stage III/IV epithelial ovarian cancer and small volume disease
19. High-dose cisplatin carboplatin chemotherapy in primary advanced epithelial ovarian cancer
20. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer
21. Phase III trial of cisplatin or paclitaxel, versus their combination in suboptimal stage III and IV epithelial ovarian cancer: Gynecologic Oncology Group Study No. 132